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This thesis targets cyclic peptide supramolecular structures for biomaterial 
applications.  The introduction gives a brief insight into supramolecular interactions, 
peptides, and their application in biomaterials.  These supramolecular interactions range 
from the weak forces of electrostatics and van der Waals interactions, to hydrogen 
bonding and metal-coordination.  The application of peptides and supramolecular 
interactions has become a highly studied area of chemistry, which has quickly gotten 
attention in the area of biomaterials.  The use of peptides in biomaterials seems obvious 
since in vivo rejection of this material might be limited.  Nature can be used as a blue 
print to direct the path for hydrogen bonding motifs and metal-coordinating interactions 
and can be applied potentially towards supramolecular biomaterials.  Finally, the 
introduction reviews the use of cyclic peptides and accounts for the synthetic design of 
the cyclic octapeptide to be used throughout the thesis work.  
The second chapter of the thesis provides the details by which the synthetic 
scheme for creating the linear peptides of interest and ultimately the cyclic peptides is 
described in detail.  Many synthetic challenges were met and overcome during this thesis 
work; the most notable was overcoming purification challenges and poor amino acid 
coupling reactions that resulted in low yields.  This thesis focuses primarily on the di-
substituted pyridylalanine cyclic octapeptide, however much of the initial work on the 
mono-substituted cyclic octapepide was carried out in tandem allowing for comparison of 






 Throughout the past few centuries chemists have become increasingly competent 
with making and breaking chemical bonds.  With each passing year, more is learned 
about covalent bonding, orbitals, and how to manipulate a compound and reaction to 
obtain the desired result.  A recent growing area of chemistry is supramolecular 
chemistry.  This area is a multidisciplinary field that focuses on electrostatics, hydrogen 
bonding, van der Waals interactions, donor-acceptor interactions, metal coordination, and 
π-π interactions.1, 2  Often, these interactions are just thought of as stabilizing interactions 
and less often about how to use these interactions to benefit a desired application.  Until 
recently most of the focus has been on covalent interactions, however the intermolecular 
and intramolecular interactions of molecules have become an increasingly popular area of 
research.  The focus of how these interactions can be modified and exploited to 
chemically do new things or to mimic nature has provided a vast array of different 
applications for many different types of materials.3  Supramolecular chemistry has a 
unique impact in chemistry because the different interactions that are available for a 
chemist to choose from can be tailored for the application and environment for which the 
final compound will be used.  Unlike covalent bonding, however, the weak interactions 
that hold the supramolecular architectures together are solvent dependent which must be 
kept in mind especially when the architecture employs hydrogen bonding in an aqueous 
or polar protic environment.  Considering for example that the hydrogen bond is weaker 
than most metal coordination interactions, knowing how to optimize the hydrogen 
bonding arrays using appropriate solvents may be just as effective synthetically as using a 
metal coordinated species.  
2  
 Supramolecular architectures have numerous applications in all areas of science; 
however, one of the fastest growing areas of research uses supramolecular architectures 
for biomaterials purposes.4  Biomaterials are materials that should be compatible with the 
body, generally the final application is for use in the human body, however many 
applications use mice or rabbits as test subjects.5  Some of the most widely proposed uses 
for the supramolecular biomaterials are as delivery applications of drugs or genes.6, 7  One 
benefit of drug delivery by this route is a targeted applications where the drug is 
administered right into the intended area where then the supramolecular architecture can 
break down releasing the drug.6  Another interesting application uses three strands of 
self-complementary peptides to create a collagen-like triple helix that is said to be highly 
biocompatible and biostable.8  Other peptides have also been used for various 
biomaterials applications including nanowires, scaffolds, channels or pores.9, 10  The use 
of peptides in this area of chemistry is a natural choice since these materials need to be 
biocompatible and the human body already employs peptides and amino acids for its 
daily uses.  Another aspect that makes peptides an excellent choice is that they are 
responsive to stimuli; thus, a change in environmental pH, temperature, or polarity can 
affect the manner in which the biomaterial responds.  A review by Stevens et al. nicely 
highlights the different aspects of peptide biomaterials in reference to their 
supramolecular interactions and applications.11  The use of peptides can offer many 
different advantages to biomaterials in the area of supramolecular chemistry.     
   
Supramolecular Chemistry and Peptides 
 On a daily basis many chemists struggle to synthesize compounds that nature 
designs and synthesizes, in unique ways.  Some of the most stunning compounds that 
nature designs are peptides, with the secondary, tertiary and even quartnary structures 
that lead to different functions.  With small changes in the primary structure of the 
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peptide, the other structures are all affected leading to a rise in differences of 
hydrophobicity, overall structure, and function.12  The primary sequence of amino acids 
can be used to tailor the outcome of the peptide’s structure and potentially its function.  
Since nature does use peptides so frequently it seems natural to take advantage of the 
many aspects of peptides and amino acids in supramolecular chemistry to create new 
applications for biomaterials. 
 Peptides offer many advantages for biomaterials applications.  One major 
advantage is the vast array of functional groups that are available or synthesized on a 
peptide backbone.  Another major advantage of utilizing peptides is that using the twenty 
common amino acids enables the body to not see the biomaterial as a foreign object, thus 
reducing the likelihood of it rejecting or attacking the device.  This is increasingly 
important as much money and time is spent on research to ensure that a device is both 
safe and effective inside the body.  In addition, the route by which peptides are created, 
by joining amino acids together, allows for the primary structure to be changed and 
unnatural amino acids to be incorporated.  Unnatural or D-amino acids are becoming 
more and more commercially available as well as other synthetically interesting amino 
acids that can be used immediately or undergo further chemical reactions to create new 
peptides.  Another advantage that proteins and peptides utilize is the many different 
stabilizing interactions to create the larger structures that are necessary for biological 
function.  Covalently, peptides use disulfide bonds which can introduce strain or lock the 
peptide into a specific conformation.13  As mentioned previously, peptides can also take 
advantage of supramolecular interactions like self-association, hydrogen bonding, and 
metal-coordination to create elaborate structures.  Each of these interactions has its own 
advantages and disadvantages that enable different applications to be more appropriate 
for certain types of interactions.   
 Self-associating peptides often have different domains which are very dissimilar 
in their hydrophobic properties.  For example one domain of an α-helix may be very 
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hydrophobic, whereas a β-sheet located close to the helix can be more hydrophilic in 
nature.  These interactions become much more important in the overall structure once 
domains have been established.  Many supramolecular architectures that use hydrophobic 
interactions appear as micelles, vesicles, or bilayers.14  Applications for such 
architectures include scaffolding, drug delivery, tissue engineering, and lipid membrane 
surfactants.15-19  This type of self-assembly is more of a non-directed route as opposed to 
hydrogen bonding or metal-coordination that are a directed route because the bonding 
interactions can be tailored to promote binding in a certain direction or orientation.  
 One of the most widely known uses of hydrogen bonding exists among DNA base 
pairs, which have been studied extensively since the 1950’s.20  The bond between a 
hydrogen atom attached to an electronegative atom and the loan pair of another 
electronegative atom in itself is a weak interaction, however nature and more recently 
chemists have learned how to maximize these interactions based on donor acceptor 
placement.21  The hydrogen bond donor is the hydrogen attached to an electronegative 
atom and the hydrogen bond acceptor is the electronegative atom with a loan pair.  By 
knowing how to properly arrange donors and acceptors on a molecule the strength of the 
overall intermolecular forces can be tuned.22  Peptides are unique in that they have many 
different ways to hydrogen bond both using the main-chain and side-chains.  In main-
chain hydrogen bonding, the amide hydrogen often serves as donor while the oxygen on 
the carbonyl group is often the acceptor.  Side-chains of peptides also contribute to 
hydrogen bonding motif both in bonding and directing the conformation of the domain.  
One of the most unique aspects of hydrogen bonding is that based on the conformation of 
the amino acids there are different types of secondary structures that arise.  Pauling and 
Corey lead the way with their work in the area of determining how the different hydrogen 
bonding domains were comprised.23, 24  There are helical as well as planar hydrogen 
bonding domains.  Each α-helix is comprised of 3.7 amino acids where the carbonyl 
oxygen hydrogen bonds with the amide hydrogen on an amino acid four residues away, 
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thus giving rise to the n+4 notation.  These can be either right-handed or left-handed 
helices and tend to have different hydrophobicities on the faces of the helix.  The planar 
or sheet motifs are referred to as β-sheets or β-strands.  These are extended lengths of 
polypeptides that can hydrogen bond with each other.  Based on how the sheets align 
gives rise to the parallel verses antiparallel hydrogen bonding. 
 However, hydrogen bonding is not just limited to peptide chains; their use in the 
biomaterials realm can be combined with polymers to increase their effectiveness.  One 
such application is for poly(ethylene urethane) to be used as a cardiovascular device in 
which two polymers of different mechanical moduli are hydrogen bonded together to 
create the necessary elastomeric properties needed for the application.25  Hydrogen 
bonding is also being used in caprolactone polymers to obtain the thermoplastic 
properties necessary for other cardiovascular applications.26  Potential drug delivery 
applications also arise from using a sacrificial template along with 
hydroxypropylcellulose and poly(acrylic acid) in a layer by layer method to create an 
hollow microsphere based on hydrogen bonding interactions.27  Other methods also rely 
on encapsulation but the hydrogen bonding interaction is involved in hydrogen bonding 
the drug and material together not the material and the body.28  Peptide nanotubes that are 
used for transport or even for electronically active biomaterials are also being designed 
using hydrogen bonding and peptide-based biomaterials.29   
 The last supramolecular interaction to discuss is metal coordination, though 
solvent dependent, it can be amongst the strongest of all the supramolecular interactions.  
The predominate advantage of metal-coordination is the highly directional binding that 
occurs between the metal and the desired ligand.  Whereas, with hydrogen bonding there 
may be multiple donors and acceptors, using metal-coordination interactions there is a 
clearly defined metal center and binding ligand(s), which can be optimized over other 
metal ligand interactions to be thermodynamically favorable.  Chemists take their 
inspiration from nature in proteins like the zinc finger in which cysteine and histidine 
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bind the zinc ion to make the protein active for RNA transcription.30, 31  However, the 
science of supramolecular architectures and metal coordination really grew in the area of 
rotaxanes, calixarenes, calixcrowns, and other larger coordinating ligands.32-35  The area 
of biomaterials using metal coordination, while synthetically challenging, is not new for 
peptide chemistry.  To date one of the most elegant uses of metal peptide interactions is 
the ruthenium and peptide coils.36  This research has inspired part of the design of this 
thesis’ supramolecular architecture, which will be discussed in greater detail later.  In 
addition there are other systems that use different peptide ligands to mimic collagen and 
receptors.37, 38  Unfortunately, most applications that employ metal-peptide coordination 
still lie outside the realm of biomaterials.   
 Each of the different supramolecular interactions has their own place within the 
world of biomaterials, as well as helping to contribute to this thesis.  Their relationship 
will be further elaborated on later on during this work to show how each type of 
interaction, no matter how small, plays a large role in helping cyclic peptides find its 
place within biomaterials applications.          
   
Prior Use of Cyclic Peptides in Supramolecular Chemistry 
 Ghadiri has pioneered the work in the area of cyclic peptides along with metal-
peptide coordination since the early 1990’s.39-41  These peptides are small cyclic peptides 
that have even numbers of alternating D- and L-amino acids that allow the backbone of 
the ring to be planar.41  This planar ring allows for the amide proton and the carbonyl of 
another ring to intermolecularly hydrogen bond allowing for vertical self-assembly of 
peptide nanotubes, see Figure 1.1.  
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Figure 1.1 Cyclic peptide vertical self-assembly through hydrogen bonding.  Image taken 
from reference41  
 
 This antiparallel β-sheet stacking produces a highly ordered peptide nanotube that 
allows for the amino acid side-chains to exist on the periphery of the cyclic peptide.  This 
is important to remember for application purposes because the peptide’s hydrophobicity 
can easily be changed by changing the amino acids.  Since the residues of the amino 
acids lie on the outside of the cyclic peptide structure the inner core of the nanotube is 
hollow.  The diameter of the hollow nanotube can be tuned by changing the number of 
amino acids within the cyclic peptide.  For example a cyclic octapeptide has an inner 
diameter of 7.5 Å, while an cyclic dodecapeptide has an inner diameter of 13 Å.42, 43  The 
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inner diameter of the nanotube plays a critical role in its applications.  The predominant 
application for peptide nanotubes is as transmembrane channels, where the membrane is 
imbedded into a lipid bilayer and allows for the passage of small molecules or ions 
through the nanotube.  Water molecules, glucose, glutamic acid, sodium and potassium 
ions have all been shown to pass through different sized transmembrane nanotubes.44-48  
Furthermore, cyclic peptides can be used inside an existing pore for binding.49  In 
contrast to using the inner core for transport, a 1,4,5,8-napthalenetetracarboxylic diimide 
side-chain attached to a cyclic peptide has been used to create an electronically active 
peptide nanotube.29  Another cyclic peptide system takes advantage of the close side-
chain interactions to control fluorescent signal between homo and heterodimers.50  Cyclic 
peptides have also shown to be active as antiviral and antibacterial agents.51, 52  
Biosensors have also been proposed by supporting a cyclic peptide nanotube onto a self-
assembled monolayer.53  
 The biomaterial applications of cyclic peptides provide the motivation for this 
thesis: to improve the transport of small molecules across a lipid bilayer with cyclic 
peptides and metal-coordination.  A well-designed system in which a cyclic peptide 
species can undergo metal-coordination with a metal complex could potentially allow for 
a well-defined supramolecular arrays consisting of peptide nanotubes that effectively 
maximize the transport of small molecules or ions across a lipid bilayer.  The 
hydrophobic nature of amino acids can be used to make the periphery of the cyclic 
peptides hydrophobic, thus allowing for better interaction with the hydrophobic lipid 
bilayer.  Hydrogen bonding between cyclic peptides allows for the vertical self-assembly 
of the nanotubes and minimizes defects.  The last supramolecular interaction used is 
metal coordination which can tether two cyclic peptide nanotubes to one another.  The 
proposed route to joining the cyclic peptides together is through a pincer molecule.  A 
pincer, as shown in Figure 1.2, can coordinate to a cyclic peptide through nitrogen 
containing amino acids, which will be discussed later.  This pincer complex has been 
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studied by the Weck group and others and has shown to be effective due to being 





Figure 1.2  Bis-pincer molecule: M= metal center (Pd, Pt), L= Ligand, E=neutral 
electron donor (S, N, P). 
 
 Each metal center of the pincer complex takes advantage of the platinum or 
palladium’s preference to be square planar with four ligands.  The nomenclature comes 
from what atom occupies the two electron donor positions labeled E.  If, for example they 
are occupied by sulfur the resulting complex is called a SCS-pincer complex, while the 
use of a nitrogen would lead to an NCN-pincer complex.56  Figure 1.3 shows how a 
single bis-pincer molecule can coordinate to two cyclic peptides. 
Figure 1.3  Pincer molecule joining two cyclic peptides together. (X=H or CH3) 
 
 By aligning the peptide nanotubes in a vertical fashion with one another the 
transport across the membrane is thought to be greater because the nanotubes can align 
the plane of the peptide ring parallel with the air-water interface.57       
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Figure 1.4  Alignment of peptide nanotubes in a lipid membrane.  A) A single nanotube 
in a membrane matrix, B) Multiple peptide nanotubes arranged in an orderly fashion, C) 
Random arrangement of peptide nanotubes within the lipid bilayer.58   
 
 Theoretically, there are many different orientations of peptide nanotubes within a 
lipid bilayer.  Figure 1.4 shows that the peptides can be parallel with the lipid bilayer (a 
and b) randomly scattered within the bilayer itself (c).  By having the nanotubes metal-
coordinated to one another it could be possible to achieve an arrangement more like (b) in 
that the peptide nanotubes are closely packed and run parallel with each other, thus 
allowing for maximized transport through the lipid bilayer.  Ghadiri has explored the use 
of a hydrogen bond motif using glutamic acid side-chains to hold peptide nanotubes 
together, however a metal-coordinated system would have stronger association 
constants.59  Another advantage that metal-coordinated systems might have over 
hydrogen bound systems is that inserting the metal-coordinated nanotubes might be 
entropically favorable since glutamic acid and hydrophobic tails of the lipid bilayer 
would not want to associate together.  While the targeted research would not yield the 
first metal-coordinated peptide nanotubes, it would be the first peptide nanotubes that are 
joined together to form a complex array of peptide nanotubes using metal-coordination.  
Previously, Kimura and coworkers used three terpyridine ligands on a cyclic peptide to 
complex copper, however the copper can only accommodate one terpyridine ligand per 
copper ion thus it is not useful for joining two peptide nanotubes together.60  Another 
method that has been described to tether peptide nanotubes together uses a covalently 
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bound azobenzene between two cyclic peptides, much like the pincer would do; however 
this azobenzene is UV active and when irradiated with UV light it folds one cyclic 
peptide onto the other which defeats the purpose of tethering together for this thesis’ 
application.61, 62   
 The research design for this thesis is based on the work by Ghadiri.  The material 
described in this thesis focuses on the efforts of the peptide synthesis to include an 
alternating amino acid sequence that consisted of D-alanines and L-phenylalanines.  One 
aspect of peptide nanotubes that must be taken into account is the characterization of the 
cyclic peptide supramolecular structures.  Initially, it would be too overwhelming and 
insoluble in most solvents to work strictly with the vertically self-assembled peptides.  
Therefore, N-methylation of the amide backbone on one face of the molecule effectively 
blocks hydrogen bonding on one face, allowing only for dimerization of the cyclic 
peptides.63  Once the amino acid sequence was set, the focus turned towards the ligand 
for metal-coordination.  Turning towards nature, we see that nitrogen based amino acids 
are capable of binding to metal centers.  It has also been shown that pyridine is an 
established ligand for the pincer complex.  Furthermore, pyridine is structurally similar to 
the phenylalanine residues in the peptide species helping it to be more symmetrical.56, 64  
Therefore, a prior graduate student in the group, Warren Gerhardt, tested the position of 
the nitrogen and the effect of the linker to the amino acid on the pyridine containing 
amino acid to determine which had the highest binding constant with the pincer metal 
center.65  It was determined that a 4-pyridylalanine was the best ligand for the pincer 
during the study, therefore the final cyclic peptide would consist of D-N-methylated-
alanine, L-phenylalanine, and L-4-pyridylalanine residues.  Fortunately, all of those 
amino acids are commercially available albeit expensive.  Initial synthetic routes towards 
the cyclic peptide species called for one L-4-pyridylalanine per cyclic peptide molecule.  
This would allow characterization to be easier by having just one site for binding to a 
metal center.  Using a mono-pincer and a tripeptide containing the L-4-pyridylalanine, 
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initially, gave a Ka value >1200 M-1.65  However, to join more than one nanotube 
together, a bis-pincer would need to be used  
Figure 1.5 Monopyridyl cyclic peptide species with bis-pincer 
 
and would create the “sunglasses” peptide similar to Figure 1.5 where the X’s represent 
methyl groups blocking hydrogen bonding on one face. After the mono-pyridyl system 
had been explored the dipyridyl cyclic peptide species shown in Figure 1.3 could be 
investigated.  
 This system would be much more complex to characterize but is ultimately one of 
the first major steps in showing that long range supramolecular arrays based on peptide 
nanotubes are feasible.  Once the characterization is complete on the N-methylated 
alanines of the cyclic peptide species, the system can be extended to explore the non-
methylated cyclic peptide species that would self-assemble vertically through hydrogen 
bonding forming the desires peptide nanotubes, while being able to self-assemble 
horizontally using metal-coordination.  Futhermore, the transport of small molecules 
across the membrane could be investigated using the dipyridyl cyclic peptide nantoubes.   
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CHAPTER 2 
CYCLIC PEPTIDE SYNTHESIS AND RESULTS 
 
Research Design 
 Throughout the years, the synthetic design for the peptide project has changed.  
The foundation of alternating D-alanine and L-phenylalanine residues has always been 
the primary goal of the cyclic peptide, along with the L-4-pyridylalanine as the metal 
coordinating species.  However, the positions of the methyl groups on the amide 
nitrogens, along with the route to synthesis of the cyclic peptide, have been varied.  Initial 





Figure 2.1  Initial linear octapeptide to be synthesized by Warren Gerhardt (compound 1) 
 
 The goal of this thesis, however, is the synthesis of the di-substituted 
pyridylalanine cyclic peptide, as shown in Figure 2.2.  Depending on the synthetic route 
explored, the X’s in Figure 2.2 can represent hydrogen or a methyl group.  The last 
synthetic route taken placed methyl groups in the amide positions of the D-alanines.  As 
previously stated the methyl groups prevent hydrogen bonding on one face of the 
molecule allowing for better characterization.  The methyl groups also require that the 
subsequent coupling be completed twice to ensure that the following amino acid in the 
sequence does indeed get fully coupled to each position on the resin; without this an 











Figure 2.2  Di-substituted pyridylalanine cyclic peptide (X=H, Me) (compound 2) 
 
 Different synthetic routes were explored to obtain the purified cyclic peptides.  
Some routes involved a solution phase approach and others involved a solid phase 
approach with utilizes a polymer based resin.  
 
Solution Phase 
 Solution phase synthesis offers many advantages over the solid phase approach.  
The first advantage is the scale on which the reactions can be carried out (gram scale) as 
opposed to the milligram scale for solid phase approaches.  Often solution phase 
synthesis can offer higher yields and fewer steps.  Since the di-substituted peptide has a 
repeating unit it can be synthesized as a tetra-peptide in the solution phase approach and 
be coupled to itself, rather than coupling eight amino acid units together.  This saves time 
and money since there are fewer coupling and purification steps.  This approach also uses 
fewer equivalents of starting material, usually just one equivalent to ensure full coupling.  
However, the drawbacks of this approach are more difficult purification steps and 
solubility issues.  The peptide has to be recrystallized or chromatographed over silica gel 
between coupling steps to remove any remaining amino acids and coupling agents.    
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 Solution phase peptide chemistry can use different types of protecting groups, 
however this thesis focused on using a benzyl protecting group for the carboxylic acid on 
the C-terminus of the peptide and a Boc (tert-butyl dicarbamate) protecting group for the 
N-terminus of the peptide.  The amino acids used for this synthesis are purchased with 
the Boc group already in place.  When treated with the trifluoroacetic acid the Boc group 
leaves the peptide as 2-methylprop-1-ene, which is a gas at room temperature eliminating 
other purification steps during the synthesis.  
 
Figure 2.3  Initial solution phase synthetic scheme (compound 3) 
 
 The initial solution phase synthetic scheme is shown in Figure 2.3 above.  Since 
compound 3 is symmetric, one tetrapeptide can be made to shorten the synthetic route.  
By making the sequence alanine-phenylalanine-alanine-pyridylalanine the two ends could 
be joined easily together by splitting the product in half, deprotecting the C-terminus of 
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one portion, deprotecting the N-terminus of the other portion, and then joining the 
peptide together to create the linear octapeptide.  The above synthetic route was 
simplified, where the X represents either a carbon or a nitrogen to make a phenylalanine 
or a pyridylalanine respectively.  Thus, the first step is done twice and one di-peptide 
with phenylalanine is deprotected on one end and one dipeptide with pyridylalanine is 
deprotected on the opposite end such that coupling makes the desired tetra-peptide.  This 
route was also used in tandem for the mono-substituted pyridylalanine.  However that 
peptide is not symmetric thus more peptide coupling steps were needed to create the 
cyclic peptide.  Looking closely at this route, the only commercially non-available 
peptide was the N-methylated-L-4-pyridylalanine, which should be available via a retro 
Diels-Alder reaction.  However Warren Gerhardt determined this reaction did not 
produce the desired product under these conditions.   
 After this route failed, a new route was investigated that utilized two N-
methylated positions, still hoping to block one face of the cyclic peptide from hydrogen 
bonding, thus still creating dimers.  The two positions chosen to be non-methylated were 
phenylalanines directly across from one another, as shown in Figure 2.4.  In compound 4, 
all phenylalanine positions were methylated, leaving the non-methylated positions to the 
pyridylalanine and alanine positions.  This route was difficult in the beginning because 
coupling the third amino acid in the sequence did not always result in a tripeptide.  Rather 
the diketopiperazine, a stable 6-membered lactam, was formed.  Overcoming this 
obstacle involved using a syringe pump to slowly add the deprotected amino acid into the 
reaction vessel that contained the activated amino acid to be coupled.  This was probably 
not seen in the first synthetic route because the second amino acid in the chain was N-
methylated, which slows down couplings and intramolecular interactions.       
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Figure 2.4  Di-substituted pyridylalanine cyclic octapeptide route containing two N-
methylated phenylalanines (compound 4) 
 
 It was also noted during this synthesis that the peptide product needed to be kept 
from light once the L-4-pyridylalanine was in the sequence.  Since the peptide needed to 
be chromatographed over silica gel to remove impurities it was noticed that a degradation 
product was being formed when exposed to light.  When the product mixture was spotted 
on TLC, it would show one product, however if a TLC plate remained exposed to light 
for a brief amount of time the spot would turn yellow.  This spot would also break into 
two spots once the TLC plate was exposed to the eluting solvent.  Using preparatory high 
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performance liquid chromatography (HPLC) overcame this degradation of the peptide 
and the degradation products were not further investigated.   
 A collaboration with Warren Gerhardt resulted in the successful synthesis of the 
mono-pyridyl cyclic octapeptide.  Unfortunately, due to an impurity, the cyclic 
octapeptide work could not be published.  However, Warren Gerhardt did demonstrate in 
preliminary results that the cyclic octapeptide and pincer compounds could metal-
coordinate with one another.  
 
Solid Phase  
 The solid phase approach to peptide chemistry involves the use of a resin 
suspended in the reaction reagents to synthesize the linear peptide.  This approach can be 
very beneficial in many aspects, most notably the ease of purification and overcoming 
solubility issues.  The drawbacks of this method include limitation to milligram scale, the 
need for addition equivalents of reagent, lower yields, and more steps.  However, since 
purification of the linear peptide had been the most difficult aspect of the project when 
using solution phase chemistry, it was thought that this route was the most beneficial 
route to complete this thesis’ goal of synthesizing the cyclic peptide.   
 There are various types of resins available for peptide chemistry.66-68  The Wang 
resin was utilized throughout this thesis’ work.  Each type of resin enables different 
reagents to be used without cleaving the peptide from the resin itself.  The Wang resin 
shown in the Figure 2.5 below is cleaved by trifluoroacetic acid once the linear peptide 
has been synthesized.  Since the peptide is cleaved from the resin using TFA, the Boc 
protecting group chemistry is not suitable for this approach.  An acceptable protecting 
group strategy on Wang resin is Fmoc (9-fluorenylmethyl carbamate).     
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Figure 2.5  Wang resin (R= starting amino acid side-chain) 
 
 The spherical ball in Figure 2.5 represents the resin, followed by the Wang linker, 
the first amino acid in the series, and lastly on the far right the Fmoc protecting group.  
The Fmoc protecting strategy is very popular and all amino acids were purchased with 
the Fmoc protecting group already intact on the amino acid.69  Removal of the Fmoc is 
facile using a 20% solution of piperidine in N,N-dimethylformamide.  The Fmoc group 
was washed away as 9-methylene-9H-fluorene and did not need any further purification.     
 A solid-phase approach was based on N-methylated alanine in which the alanine 
would be coupled to the resin as the first step to avoid cyclizing with a terminal N-
methylated amino acid, Figure 2.6.  Since the first step in this synthesis was coupling the 
resin and the amino acid together it was imperative for the subsequent steps to have a 
known amino acid loading on the resin.  This can be done by cleaving the Fmoc 
protecting group from the amino acid and using a UV/Vis spectrometer to obtain an 
absorbance reading.  Once the absorbance reading is known and taking into account the 
dilution factor the amino acid loading can be determined.  Unfortunately, the Fmoc 
loadings were inconsistent and the amino acid did not seem to load onto the resin 
consistently so after checking for compound 5, as shown in Figure 2.6, this route was 
reevaluated.   
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Figure 2.6  Solid-phase approach with N(methylated) alanines and phenylalanines 
(compound 5)  
 
 Upon consent of Dr. Arora at New York University, some time on his peptide 
synthesizer was obtained in late spring of 2008.  The peptide synthesizer is an automated 
machine that used microwave radiation to speed up the coupling processes.  This machine 
did in a day what typically took two days by hand, with higher purity than what can be 
obtained by using bench top chemistry methods.  However, only one round of linear 
peptides were be made during the trip to NYU.  It was a very beneficial time and allowed 
for the non-methylated cyclic peptide to be synthesized.  As discussed previously, this 
was not the ideal peptide to synthesize however it was the easiest given time constraints.  
The linear (Ala-Pyr-Ala-Phe)2 was purified; however, cyclization of the purified linear 
peptide yielded 20 mg which did not show any cyclized product once submitted to 
reaction conditions.  The product may have just been insoluble in the solvents used to 
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obtain the mass spectrum and using MALDI-MS probably would have been too harsh 
and broken the cyclic peptide apart.    
 While in New York, a different resin than the one that was being used initially 
was suggested that would enable cyclization to occur on the resin, by-passing the peptide 
cleavage step from the resin.  This new resin was a Kenner “safety-catch” resin and 
allows for the amino acid to be coupled to the polymer resin via a sulfonamide which 
once activated by iodocyanomethane the peptide can cyclize off the resin, leaving the 
cyclic peptide.70  The synthetic scheme is shown below in Figure 2.7.  This was a very 
promising route that would enable the peptide to be made from start to finish much faster. 
 
Figure 2.7  Kenner “Safety-catch” Resin synthesis (AA represents an amino acid) 
 
This strategy also had the prospect of obtaining a purer peptide species because it would 
be cleaved off the resin as a cyclic peptide, which could precipitate out of solution.  The 
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first step was to take the Kenner resin and couple it to the first amino acid, or load the 
resin with the amino acid.  This seemed to have worked and gave consistent amino acid 
loading estimates at 0.5357 mmol/g.  The problem with this resin was the cleavage of the 
peptide from the resin.  Activating the resin for cleavage did not seem to work since there 
was never a product indicated by mass spectrum analysis.  While this route seemed to be 
promising, in the end it was abandoned for a different solid-phase route on the initial 
Wang resin.  At this time, Dr. Madhavan had begun the synthesis of the mono-substituted 
pyridylalanine cyclic peptide (Figure 2.8), compound 6, and was using N-methylated D-
alanine at every other position.  She successfully showed that the cyclic octapeptide could 
metal-coordinate with the bis-pincer.  Figure 2.9 shows the proton NMR spectrum of 
compound 6, however even after an extended period of time a 13C NMR spectrum could 
not be obtained for the compound.  A mass spectrum was obtained and has a molecular 
ion peak at 930 m/z and 465 m/z corresponds to the doubly charged species as well.     
 





Figure 2.9  1H NMR spectrum of compound 6 
 
 
Figure 2.10  Mass Spectrum of compound 6 
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 Figure 2.11 shows the aromatic region of the proton NMR spectrum for the 
coordination with the pincer complex.  It shows a shift in the peaks that corresponds to 
the pyridylalanine hydrogens, while the pincer signals become broader upon 
complexation.  In addition, the peaks belonging to the phenylalanine hydrogens do not 
shift, thus the phenylalanine does not interfere with the metal-coordination of the pincer 
and the cyclic octapeptide.   
 
Figure 2.11  1H NMR spectrum of cyclic peptide and bis-pincer complex  (2:1 ratio) 
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 To have a good comparison study with the mono-substituted peptide the 
following synthesis for the di-substituted peptide was completed (Figure 2.12).   
 
 
Figure 2.12  Linear octapeptide containing N-methylated alanines (compound 7) 
 
 This was the last synthetic scheme explored.  This route still deals with a very 
little linear product cleaved from the resin and after purification via HPLC there is 
typically about 50 mg that can be cyclized using the appropriate scale for the peptide 
reaction vessel.  The cyclization product has not been obtained in a high enough purity to 
obtain the necessary characterization data for publication and studies with the pincer 
complex.  However, a mass spectrum of the cyclized octapeptide shown in Figure 2.13 
was obtained that shows an [M+H]+ peak at 931m/z and the [M+2H]+ at 932m/z.  A 
proton NMR spectrum of the disubstituted pyridyl cyclic octapeptide was obtained and is 
shown in Figure 2.14.  A carbon NMR spectrum was also attempted, however, as Dr. 
Madhavan experienced relaxation times were too long to obtain a complete spectrum 
given overnight data aquisition.  
 Two-dimensional NMR studies were carried out for both cyclized peptide 
compounds.  The first study completed for compound 6 was COrrelation SpectroscopY 
(COSY).  This methods shows which protons are spin-spin coupled and for peptides this 
can help to assign the 1D proton NMR spectrum since these spectra are often complex.  
This was a very useful method since the monopyridylalanine cyclic peptide is not 
symmetric like its disubstituted counterpart.  The COSY spectrum (Figure A.1) was most 
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helpful in differentiating the pyridylalanine aromatic signals at 8.60 ppm and 7.68 ppm 
from the phenylalanine peaks at 7.20 ppm.  The second 2D NMR experiment was TOtal 
Correlation SpectroscopY (TOCSY) (Figure A.5) which shows the signals from the 
COSY but also protons that are spin-spin coupled further than three bonds away.  The 
TOCSY was helpful in determining the position of the N-methyl groups at 2.48 ppm 
from the CH2 groups on the phenylalanine and pyridylalaninine.  Since these CH2’s are 
so close together it differentiated between the pyridylalanine CH2 at 2.81 ppm from the 
phenylalanine CH2 at 2.61 ppm.  Unfortunately, given the overlap in the spectra, the 
alanine spin-spin systems could not be distinguished.  A ROESY experiment (Figure A.7) 
was also completed, however it did not provide any more insight than the previous 2D 
studied did.   
 Two dimensional NMR studies for the compound 7 were also completed.  
However, due to impurities there is not as much information gained from them.  The first 
2D NMR study was a COSY experiment (Figure A.8) which showed the connectivity 
between the pyridylalanine aromatic protons at 7.73 and 8.76 ppm.  While the mass 
spectrum showed the molecular weight of the cyclic compound to be correct (Figure 
2.13), the 2D NMR experiment shows that an impurity is present, possibly an incorrect 
peptide sequence.  Initially, it was thought that there was an extra CH3 alanine peak due 
to different conformations of the cyclic peptide species, however further investigation of 
the spin-spin correlations makes it appear that not all of the alanines are N-methylated.  
There are clear CH3 correlations between a CH3 at 1.22 ppm and a CH at 4.7 ppm, which 
also correlates to an NH proton at 8.60 ppm.  A structural discrepancy was not apparent 
in the MS but is clearly evident by the NMR data.  One possibility for the discrepancy 
lies in an impure starting material, however one would expect that more positions would 
show up non-methylated since coupling an alanine would be greater and thus give 
inaccurate MS results.  Therefore, a second hypothesis is that during cyclization the 
terminal methyl group was cleaved before cyclization could be completed.  It would not 
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make sense for a degradation route to be a problem since the MS and NMR spectra were 
taken so close together.  The second 2D NMR experiment began was a Heteronuclear 
Single Quantum Coherence (HSQC) study (Figure A.14) which shows carbon to proton 
spin-spin connectivity.  However, due to slow carbon relaxation times the study was 
abandoned.  A larger sample and much longer times on the instrument would be needed 
to obtain useful HSQC data.  Even without the carbon spectra present it is still possible to 
see the peaks and gain some carbon NMR data from the spectra.  The 2D NMR data 
suggests that next round of cyclic peptide synthesized needs to be purified better in order 
to determine what has lead to the additional peak that was found in the NMR data, 
unfortunately the DMSO used for characterization prevents further purification methods 
from being explored.                    
  
 




Figure 2.14  Proton NMR spectrum of compound 7 
 
Experimental Section 
Materials and Methods:  
 All peptides were commercially available from Peptech Corp. and Peptides 
International.  DIEA was distilled over calcium hydride and the DCM was dried by 
passing it through a Cu2O and alumina column.  DMF, pyridine, and piperidine were 
purchased dry from Alfa Aesar.  NMR spectra were aquired on a Bruker DSX 300 at 298 
K  (1H NMR: 300 MHz, 13C NMR: 75MHz).  All chemical shifts are reported in parts per 
million (ppm), using the solvent as an internal standard.  Data are reported as follows: 
chemical shift, multiplicity, coupling constant, and integration.   
  
Benzylation method for protecting amino acid carboxylic acids: 
 Boc-alanine (10.026 g, 52.9 mmol) was added to a solution of DMAP (1.292 g, 
0.032 mmol), DCC (10.924 g, 53 mmol), and benzyl alcohol (5.5 mL, 211 mmol) was 
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added to a 100 mL round bottom flask with 10 mL of DCM on ice.  A precipitate formed 
immediately and the reaction was worked up the following day by filtering over celite 
using ethyl acetate to wash the precipitate.  The excess solvent was removed via reduced 
pressure and the solid was redissolved in ethyl acetate and placed in the fridge.  If more 
precipitate crashed out of solution then it was filtered over celite, otherwise the solution 
was washed with 0.5M HCl and 0.5M NaOH.  Afterwards excess benzyl alcohol was 
removed using a kugelrohr yielding a white solid (17.46 g, 88.5%).     
 
Method for removing the Boc protecting group: 
 Benzyl 2-(tert-butoxycarbonylamino)propanoate (4.513 g, 16.2 mmol) was 
dissolved in a round bottom with 20 mL of DCM and 10 mL of TFA under argon.  After 
an hour and a half the solvent was removed under vacuum and then placed under vacuum 
overnight to try thoroughly.  This solid was used without further purification.     
 
General method for coupling amino acids via solution phase: 
 Benzyl (2-methylamino)propanoate (4.78 g, 15.2 mmol) and 2 mL of DIEA were 
added to 30 mL of DMF.  Fmoc-L-4-pyridylalanine (2.08 g, 7.79 mmol), HOBT (1.05 g, 
7.7 mmol), PyBOP (4.45 g, 8.5 mmol), and 2mL of DIEA were added into 20 mL of 
DMF to activate.  The second reaction mixture turned yellow upon addition of the DIEA 
to solution and was subsequently added to the first reaction mixture.  After six hours, the 
DMF was removed under vacuum using an extra trap.  The solid was redissolved in ethyl 
acetate and washed with saturated sodium bicarbonate solution and dried over 
magnesium sulfate.  The ethyl acetate was then removed under reduced pressure and 
dried overnight, if necessary a column using silica gel and 1:1 EtOAc and hexanes can be 




General method for debenzylation of peptide: 
 The benzyl protected linear peptide was dissolved in ethanol (15 mL) in a 
pressure flask, a catalytic amount of Pd/C (10%) was added and secured in the Parr 
hydrogenation apparatus.  The mixture was pressurized in a hydrogen atmosphere to 50 
PSI and shaken for 24 hours, after which it was filtered over celite and the solvent 
removed under reduced vacuum to give a white solid, used without further purification.   
 
General method for coupling amino acid onto resin:  
Wang resin (517 mg) was added to a peptide vessel containing 5 mL of DMF.  This 
mixture was allowed to swell under argon for 15 minutes.  N(Me)-alanine (1eq, 450 mg), 
2,6-dichlorobenzoyl chloride (1.1 eq, 0.25 mL), and pyridine (1.1 eq, 0.25 mL) was 
added into the reaction vessel and reacted overnight.  The next morning the resin was 
rinsed three times with DMF and DCM.  The resin loading was tested using the method 
from Gude.71 
 
General method for linear octapeptide by solid-phase synthesis: 
 The linear octapeptide was synthesized via a solid phase peptide synthesis 
strategy using an Fmoc-phenylalanine functionalized Wang resin.  The synthesis was 
carried out in a solid phase synthesis vessel where the resin was first swelled with CH2Cl2 
for 45 min., following which it was washed with DMF.  The Fmoc groups were 
deprotected by treating the resin with a 20% solution of piperidine in DMF to give a free 
amine.  A solution of three equivalents each of Fmoc-D-N(me)-alanine, HATU and 15 
equivalents of DIEA in 5 mL of DMF was added to the vessel and allowed to react with 
the resin for 30 min.  Argon was bubbled through the flask in order to ensure mixing of 
the resin and the reagents.  After the resin was thoroughly washed, the Fmoc protecting 
group was removed and another round of peptide couplings could progress according to 
the synthetic scheme.  Following ever N(methylated)-alanine the coupling was done 
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twice to ensure proper loading of the subsequent amino acid.  After the linear octapeptide 
sequence was completed, the resin was rinsed well with DMF, DCM, and MeOH.  
Following the washes the peptide was cleaved from the resin using 5% TFA in DCM.  
The liquid was then removed under reduced pressure to yield an impure solid which was 
purified by reverse phase HPLC using a gradient of water containing 1% TFA and 
acetonitrile.    
 
Cyclization procedure: 
 Monosubstituted pyridylalanine octapeptide (compound 7) (84 mg, 0.079 mmol) 
was added to a round bottom flask with 115 mL of DMF.  PyAOP (123.6 mg, 0.237 
mmol) and DIEA (82 µL, 0.475 mmol) was added and allowed to react under argon for 
three hours.  Afterwards, a secondary trap was used to remove the solvent and the residue 
was purified by reverse phase HPLC using a gradient of acetonitrile and water with 1% 
TFA.  The fractions were collected and the HPLC solvents were removed under reduced 
pressure and the remaining liquid was lyophilized off to give a solid (45 mg, 61%).  1H 
NMR (300 MHz, DMSO) δ: 0.81 (t, J= 36.0, 3H), 0.99 (dd, J= 5.8, 11.2, 3H), 1.05 (dd, 
J= 9.3, 17.4, 3H), 2.54 (s, 3H), 2.57 (s, 3H), 2.63(s, 6H), 2.79 (m, 12H), 4.57-5.14 (m, 
8H), 7.14-7.28 (m, 15H), 7.71 (m, 2H), 8.04-8.45 (m, 2H), 8.69 (m, 2H);  MS (ESI) 
positive mode 930.6m/z.   
 
Future Work 
 There is still much work to be done on the cyclic octapeptide project.  Most of the 
time spent on this project involved synthesizing and purification of the linear and cyclic 
octapeptides.  If time was available on the automated peptide synthesizer at New York 
University larger amounts of the peptide could be obtained and purified at a much faster 
rate.  However, the synthetic route is effective at synthesizing the linear peptide and 
reverse phase HPLC is helpful in the purification of both the linear and cyclic peptide 
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products.  Unfortunately, the target molecule for this thesis, the disubstituted 
pyridylalanine, while being in hand, is present as a mixture with impurities that HPLC 
has not been able to resolve.  Perhaps recrystallization could be used to purify the 
compound further.     
 Once the purified peptide is obtained and characterized the metal-coordination 
step with the pincer, both mono- and bis- can be evaluated.  The Weck group has 
extensively synthesized and studied metal-coordination interactions using pincer 
molecules so this aspect of the project should not cause a stumbling block.72, 73  The 
mono-palladium pincer is used to show the binding constant, however comparison to the 
mono-substituted pyridylalanine cyclic octapeptide will give the best data since the 
binding ratio of pincer to peptide would be 1:1.  The use of the bis-palladium pincer 
enables the supramolecular structure to be elongated along the horizontal axis and with 
multiple pyridines and a bis-pincer the binding constants may get difficult to fully 
determine.  The solubility of the cyclic octapeptide with the bis-pincer also makes 
characterization difficult.  If it precipitates from solution upon coordination then electron 
miscroscopy may be the only route to characterization.  However, if it remains soluble 
then possibly gel permeation chromatography, MALDI-MS, dynamic light scattering, x-
ray crystallography, and proton NMR spectroscopy may help to characterize the system.     
 After the characterization of the disubstituted pyridylalanine and fully N-
methylated alanine cyclic octapeptide, the non-methylated cyclic octapeptide can be 
synthesized.  The peptide brings with it its own set of challenges, which include 
significant characterization hurdles.  Since the methyl groups will no longer be present to 
block one face of the molecule the cyclic peptides can hydrogen bond with one another to 
form the peptide nanotubes that Ghadiri’s group has explored significantly.  After metal-
coordination of the non-methylated cyclic octapeptide the peptide project would then 
have met its primary long-term goal synthetically.  The nanotubes can be placed into lipid 
bilayers and hopefully show that the alignment of the peptide nanotubes benefits from the 
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metal-coordination.  This will be difficult to prove, however using a control flow study 
that shows the difference in directional flow across the lipid bilayer with and without 
metal-coordination could be key.  It is hoped that the metal-coordination will align the 
peptide nanotubes in a vertical fashion together, and if this is achieved once placed into 
the lipid bilayer the flow across the membrane with the metal-coordination should be 
greater.   
 Over the course of this thesis, we have learned much about peptide chemistry. 
Specifically, the two approaches of solid and solution phases were explored.  The 
benefits of each route are now understood.  For this cyclic peptide purification is the most 
significant issue; therefore the solid-phase synthesis is the optimal route due to the 
peptide being purer once cleaved from the resin.  Both routes struggled with the 
diketopiperazine by-product and reaction conditions had to be optimized to avoid this by-
product.   
 In conclusion, the goal of this thesis was to synthesize a disubstituted 
pyridylalanine cyclic octapeptide.  Full characterization has not been accomplished due to 
impurity, solubility, and extremely long carbon nuclei relaxation times.  It is hoped that 
by the work in and leading up to this thesis that the application of cyclic octapeptides will 
find use in biomaterials such as transport across lipid membranes.  
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APPENDIX A 
2-DIMENSIONAL NMR DATA OF CYCLIC PEPTIDES 







Figure A.2 COSY 7.2-9.0 ppm range 
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Even though all the alanine, phenylalanine, NH’s, and N-methyl groups are not 
equivalent to each other the signals could not be conclusively assigned for each 
individual amino acid in the cyclic octapeptide.  
 
N(me)-Alanine signals: 
Ha= 2.48 ppm     N-Me CH3 
Hb= 4.50-5.20 ppm   CH  
Hc = 0.80, 0.90, 1.00, 1.30 ppm  CH3  
 
Phenylalanine signals: 
Hd= 7.75-8.42 ppm   NH (overlapping with pyridylalanine NH) 
He= 5.13 ppm    CH 
Hf= 2.61 ppm    CH2 
Hg= 7.20 ppm    aromatic protons 
 
Pyridylalanine signals: 
Hh= 7.75-8.42 ppm   NH (overlapping with phenylalanine NH) 
Hi= 4.81 ppm    CH 
Hj= 2.81 ppm    CH2 
Hk= 7.68 ppm    aromatic protons 
Hl= 8.60 ppm    aromatic protons 
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2D NMR assignments of compound 7: 
 
 
The HSQC was not complete; therefore the proton-carbon assignments could not be 
assigned.  
 
N-(methyl)-Alanine Signals: Theoretically there are 2 equivalent alanines per cyclic 
peptide but these NMR studies cannot distinguish them from one another 
Ha= 2.50 ppm    N-CH3 
Hb= 4.70 ppm, 5.14 ppm CH 
Hc= 0.77ppm, 1.02 ppm CH3 
 
Pyridylalanine Signals: 
Hd= 7.90 or 8.18 ppm  NH cannot distinguish from phenylalanine NH signal 
He= 4.91-5.05 ppm  CH overlap with phenylalanine CH signal 
Hf= 2.82-3.04 ppm  CH2 overlap with phenylalanine CH2 signal 
Hg= 7.73 ppm   Aromatic proton 
Hh= 8.76 ppm   Aromatic proton 
 
Phenylalanine Signals: 
Hi= 7.90 or 8.18 ppm  NH cannot distinguish from pyridylalanine NH signal 
Hj= 4.91-5.05 ppm   CH overlap with pyridylalanine CH signal 
Hk= 2.82-3.04 ppm  CH2 overlap with pyridylalanine CH2 signal 
Hl= 7.20-7.35 ppm  Aromatic proton 
 
Non N-(Me)-Alanine 
1.22 ppm    CH3 
4.70 ppm   CH 




AN ALKYNE FUNCTIONALIZED LACTIDE MONOMER 
 
Introduction 
 Poly(lactic acid), (PLA), has gained popularity in recent years due to it being a 
biorenewable resource and its potential applications in the medical community by being 
biocompatible and biodegradable.74  Proposed and current medical applications of PLA 
include sutures, stents, drug delivery, among others, however.  This appendix of the 
thesis targets the use of functionalized PLA-based polymeric systems as novel materials 
for bone scaffolding.  
  The need to functionalize lactide monomers stems from the fact that without such 
modification there is little that can alter the polymer in terms of biocompatibility, tissue 
adhesion, hydrophobicity, degredation rates, and mechanical strength.75  Also, it allows 
for the post-polymerization functionalization with of biological moieties.  Previously 
functionalized lactide monomers by the Weck and Collard groups have focused on 
serines or lactides functionalized with sugars.  This project proposed a lactide monomer 
(Figure B.1) that is functionalized with an alkyne group that can undergo post-
polymerization reactions including 1,3 dipolar cycloadditions.  
 
Figure B.1: Lactide monomer 
 
Results and Discussion 
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 The synthesis of the alkyne lactide monomer is shown in Figure B.2 below.  The 
starting product is a commercially available amino acid that is available in racemic and 
enantiomerically pure forms.  However, to reduce costs, the racemic starting material was 
always used.  Overall, the functionalized lactide monomer is made with an overall yield 
of 21% from start to finish.  The starting material being an amino acid allows for the 
synthetic scheme to be opened to a larger library of lactides, each bringing with it its own 
properties and benefits.      
 
Figure B.2: Synthesis of lactide monomer 
 
 Polymerization of the functionalized lactide occurs through a ring-opening 
polymerization using stannous octoate as catalyst and t-butyl benzyl alcohol as the 
initiator.  Stannous octoate offers the benefit of being an approved catalyst for medical 
applications.76  Another initiator besides the t-butyl benzyl alcohol is a norbornene 
polymer chain with an alcohol group on one end.  The benefits of using the norbornene 
polymer initiator is that it can provide rigidity to the polymer chain and help to alter the 
properties of the overall co-polymer for the target bone scaffolding application.  Wang et 
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al. recently published the use of a norbornene initiator for use with lactide monomers to 
form highly porous scaffolds that could be beneficial for bone scaffolding.77  After the 
copolymerization of the functionalized lactide monomer with the norbornene initiator the 
foaming process is based on thermally induced phase separation (TIPS) to successfully 
create the necessary and reproducible pore size.78  By dissolving the polymer in a solvent 
followed by freeze-drying endows the remaining material with the desired porous 
structure.  After creating the pores the cross-linking can be done using a photo cross-
linkable agent to further set the polymer.   
 This post-polymerization occurs through a 1,3-dipolar cycloaddition with an azide 
functionalized moiety that can be a PEG chain for solubility, peptide sequences for cell 
adhesion, or even biotin for binding studies.  Figure B.3 below shows the monomer 
polymerization and a simplified view of the products after the 1,3-dipolar cycloaddition. 
 




 The copolymerization of this monomer with lactic acid maintains the 
biodegradation needed for bone scaffolding applications and minimizes the amount of 
functionalized lactide monomer needed.  As stated before, the azide for the 1,3-dipolar 
cycloadditions can contain a library of different biological moieties, but we were mostly 
interested in peptides, sugars, and biotin.  A small poly(ethylene glycol) chain could be 
used as well but this does not affect how the polymer works biologically except for 
altering its hydrophilicity.  The 1,3-dipolar cycloaddition is often referred to as “click” 
chemistry and offers benefits of being widely applicable due to mild reaction conditions, 
high yield, and byproducts that are easily removed.79  In this case it enables the polymer 
to undergo various different routes of functionalization through the same chemical route.  
The high yielding post-polymerization step is also a necessity because the monomer is 
made in such a low yielding synthesis and was copolymerized with lactide that it must be 
high yielding to achieve the maximum results desired.   
 Synthesis of the alkyne functionalized lactide monomer has been the most 
difficult process of this project.  Over the years, each step in the synthesis of the alkyne 
functionalized lactide monomer has resulted in the reevaluation of the synthetic strategy.  
Buying new reagents, trying different water sources and many other synthetic steps have 
been taken to provide what little monomer has actually been made.  Different solvents, 
acids, and bases were also explored, but did not offer any further insight into how the 
reaction scheme could be optimized.  Using different proton sources, like acetic acid, 
TFA, or even sulfuric acid,  during the alpha hydroxyl acid synthesis also did not provide 
any insight into the yields, however the -2 oC ice water bath for the reaction did seem to 
provide the optimal results for the product synthesis.  Using an amine to sequester the 
HCl formed in situ during the coupling step of the alpha hydroxy acid to the acid chloride 
did not seem to affect the yield of the product and in turn made the purification more 
difficult.  Trying to cyclize the monomer without switching the halogen to iodine did not 
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provide the desired cyclized product.  Longer reaction times also did not seem to give rise 
to higher yields.  Lactide monomers from Dr. Collard’s group are often dimerized at high 
temperature for so long, however the alkyne functionality may not survive such harsh 
conditions for that long of a time.  Also, the dimerized product may interfere with the 
1,3-dipolar cycloaddition post-polymerization reaction. However, a small amount of the 
alkyne functionalized lactide monomer was made through the synthetic route.  While not 
enough to complete all the characterization and desired experiments, it was adequate for a 
test polymerization reaction.  A test polymerization was carried out using 10% of the 
alkyne functionalized monomer and 90% lactide.  The reaction was complete in less than 
30 minutes using stannous octoate as the catalyst and t-butyl benzyl alcohol as the 
initiator.  A molecular weight determination was attempted by GPC, however, the GPC 
data were inconclusive.  However, end group analysis carried out by NMR spectroscopy 
suggests a molecular weight between 25,000 and 30,000 g/mol.  
 Another goal of the project is to reinforce the PLA block by using a norbornene 
polymer as the initator.  This alters the mechanical strength of the final material and has 
shown to be useful for making the necessary porosity of the foamed polymer.2  Not only 
does the norbornene polymer provides a rigid polymer backbone but can also contain 
functional groups that can alter the physical and mechanical properties of the final 
copolymer.  Such is the case with Wang’s system where a cross-linkable unit off of the 
norbornene was used to photo cross-link the material after the foaming process took 
place.  Since there was not enough of the alkyne monomer synthesized and purified the 
polymerizations off of the norbornene and 1,3-dipolar cycloaddition reactions were not 
carried out.  However, based on a recent publication from Baker’s group there is nothing 




 Since taking over this project in early 2006 many advances have been made.  A 
different synthetic scheme was chosen other than the previous one used.  In addition the 
alkyne functionalized monomer has been synthesized, although in very low quantities, 
and has shown to polymerize with racemic lactide in a short period of time.  Continued 
success on this project will come once the monomer can be synthesized in greater 
quantity.  After synthesis of the monomer is completed the polymerization reactions need 
to be fully evaluated.  Potentially changing the monomer from an alkyne to an azide 
would help in overcoming this obstacle, however the monomer and the corresponding 
dimer have been made; therefore possibly further exploring different reaction routes and 
conditions would be more helpful than doing a total monomer switch.  In addition, post-
polymerization reactions using the 1,3-dipolar cycloaddition reaction can be carried out 
with various biological moieties.  Then, polymer samples, both before and after post-
polymerization need to be given to Dr. García’s group to ensure biocompatibility. 
 In the long term, the alkyne functionalized monomer can be copolymerized with 
other monomers that our group has previous published to provide two functional handles 
on the PLA backbone.4  However, the deprotection of the benzyl groups uses 
hydrogenation and may hydrogenate the alkyne if the alkyne does not undergo the 1,3-
dipolar cycloaddition reactions prior to hydrogenation. The degradation rates and 
biocompatibility need to be evaluated.  The use of the norbornene initator also needs to 
be explored which would lead to various mechanical tests to determine the physical 
properties of the overall polymer and working to optimize the results. 
Experimental  
Materials and Methods: 
 Propargylglycine was purchased from Chem-Impex.  2-Bromopropionyl chloride, 
dry DMF and acetone were purchased from Aldrich.  D,L-Lactide was purchased from 
Aldrich and recrystallized in dry EtOAc, dissolved in benzene, lyophilized, and stored in 
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a nitrogen filled glovebox.  NMR spectra aquired on a Bruker DSX 300 at 298 K  (1H 
NMR: 300 MHz, 13C NMR: 75MHz).  All chemical shifts are reported in parts per 
million (ppm), using the solvent as an internal standard.  Data is reported as follows: 
chemical shift, multiplicity, coupling constant, and integration. 
  




 Propargylglycine (3.495 g, 30.9 mmol) was dissolved in ~120 mL of 1M H2SO4 
and cooled to -2 oC.  NaNO3 (6.40 g, 92.8 mmol) was dissolved in 60 mL of deionized 
water and added dropwise to the reaction mixture over 45 minutes under argon, allowing 
the reaction temperature to not exceed 0 oC.  The ice bath was removed 9 hours later and 
the reaction was stirred at room temperature for another 16 hours.  Then the water was 
washed with ethyl acetate, dried over magnesium sulfate, and excess solvent was 
removed under reduced pressure.  Upon removal of the solvent a yellow crystalline solid 
appeared.  Purification was completed using column chromatography (silica gel, CH2Cl2, 
MeOH, CH3COOH, H20; 42.5:5:2.5:1).  Yield: 2.6 g (74%). 1H NMR (300MHz, CDCl3) 
δ 2.15(s, 1H), 2.79 (t, J= 5, 2H),  4.42 (t, J= 3, 1H);  13C NMR (300MHz, CDCl3) δ 24.6, 
70.3, 74.9, 78.2, and 176.5; MS (ESI) negative mode 112.8 
 
Synthesis of 2-(2-bromopropanolyoxy)pent-4ynoic acid 
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 2-Hydroxypent-4-ynoic acid (2.6 g, 22.8 mmol) was dissolved in 2-
bromopropanoyl chloride and heat to 40 oC.  n-Methyl morpholine (4.5 mL, 48.4 mmol) 
was added dropwise to the reaction mixture.  The reaction was then filtered over celite 
using ethyl acetate, dried over magnesium sulfate, and excess solvent was removed under 
reduced pressure.  Excess acid chloride was removed using a Kugelrohr.  Purification of 
the brown oil was completed using column chromatography (silica gel, CH2Cl2, MEOH, 
CH3COOH; 46.5:2.5:1).  Residual acetic acid was removed using a Kugelrohr.  Yield 
3.89 g (68.5%).  1H NMR (CDCl3) δ 1.85(m, J=6, 3H), 2.07 (m, 1H), 2.83(m, 2H), 
4.50(m, 1H), 5.23(m, J=5, 1H), 9.25(b, 1H); MS (ESI) negative mode 248.7 
 
Synthesis of 2-(2-iodopropanolyoxy)pent-4ynoic acid 
 
 2-(2-Bromopropanolyoxy)pent-4ynoic acid (3.89 g, 15.6 mmol) was dissolved in 
40 mL of dry acetone and potassium iodine (15.0 g, 90.3 mmol) was added and the 
reaction mixture was closed under argon and heated to 75 oC overnight.  Residual solid 
was removed by filtration and acetone was removed under reduced pressure.  The 
resulting solid was dissolved in diethyl ether and washed with a solution of saturated 
thiosulfate (200 mL), dried over magnesium sulfate, and excess solvent was removed 
under reduced pressure.  Yield 3.69 g (79.9%).  1H NMR (CDCl3) δ 1.98 (m, J=6  ,3H), 
2.09 (m, 1H), 2.81 (m, 2H), 4.58 (m, 1H), 5.22 (m, J= 5, 1H), 9.50 (b, 1H) 
 Synthesis of 3-methyl-6-(pro-2-ynyl)-1,4-dioxane-2,5-dione 
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 2-(2-iodopropanolyoxy)pent-4ynoic acid (103 mg, 0.348 mmol) was dissolved in 
2 mL of DMF.  The solution was added to 10 mL of DMF (dry and degassed) and 
NaHCO3 (55 mg, 0.654 mmol) heated to 40 oC, via a syringe pump with an addition rate 
of 0.5 mL/h.  The reaction was left overnight, DMF was removed under reduced pressure, 
and was purified by dissolving in diethyl ether and precipitating in methanol three times.  
Yield 30 mg (52%).  1H NMR (CDCl3) δ 1.69 (d, J=6, 3H), 2.16 (t, J= 4, 1H), 2.98 (m, 
2H), 5.07(m, 2H); Elemental Analysis calcd. for C8H8O4: C, 57.14; H, 4.80; O, 38.06. 
found C, 56.76; H, 4.82; O, 38.35. 
 
SnOct2 Catalyst Stock Solution: 
 In a nitrogen-filled glovebox the stannous octoate (0.32 g, 0.8 mmol) was added 
to a 10 mL volumetric flask and filled with dry, degassed benzene.  The resulting solution 
was 0.8 M and stored in the glovebox contained in a Schlenk flask. 
 
Copolymerization procedure: 
 In a nitrogen filled glovebox, 13.5 mg(0.08 mmol) of alkyne lactide monomer, 
107 mg (0.72 mmol), 100 µL (0.0008 mmol) of 0.004 M Sn(oct)2 catalyst, and 71 µL of 
t-butyl benzyl alcohol were added to a reaction vessel along with a small amount of 
benzene (less than 1 mL) to get the solid into the bottom of the vessel.  The sample was 
then removed from the glovebox and lyophilized prior to polymerization.  Under argon, 
the reaction mixture was then heated to 110 oC and stirred for 1 hour.  The solid was 
dissolved in methylene chloride and precipitated out using cold methanol three times.  
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1H (CDCl3) δ  1.59 (d, J= 3, multiple H’s) , 2.05 (m, 1H), 2.85 (m, 2H), 5.11(q, J= 1,3,  
multiple H’s); 13C NMR racemic (300MHz, CDCl3) δ 169.17, 169.04, 168.83, 167.22, 
166.98, 168.81, 71.43, 70.51, 70.39, 69.49, 69.35, 69.08, 68.95, 68.79, 66.68, 31.22, 
21.47, 20.46, 16.80, 16.58.  
 
     Raw Data 
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Figure B.10  13C NMR spectrum for 3-methyl-6-(pro-2-ynyl)-1,4-dioxane-2,5-dione 
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